194 related articles for article (PubMed ID: 2141343)
1. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Dorman NJ; Lerner SA
J Infect Dis; 1990 Jul; 162(1):103-8. PubMed ID: 2141343
[TBL] [Abstract][Full Text] [Related]
2. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
[TBL] [Abstract][Full Text] [Related]
3. Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.
Pavie J; Lefort A; Ploy MC; Massias L; Chau F; Garry L; Denis F; Fantin B
Antimicrob Agents Chemother; 2003 Jun; 47(6):2018-21. PubMed ID: 12760890
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Reddy VN; Bailey EM; Rybak MJ
Antimicrob Agents Chemother; 1990 Nov; 34(11):2081-5. PubMed ID: 1963526
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activity of oxacillin and glycopeptides against Staphylococcus aureus in patients with endocarditis: looking for a relationship between tolerance and outcome.
Pasticci MB; Moretti A; Stagni G; Ravasio V; Soavi L; Raglio A; Vailati F; Cardaccia A; Santucci A; Papili R; Sgrelli A; Pallotto C; Baldelli F
Ann Clin Microbiol Antimicrob; 2011 Jun; 10():26. PubMed ID: 21658248
[TBL] [Abstract][Full Text] [Related]
6. Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.
Vas KE; Török Á; Cordoş B; Vancea S; Brassai A; Székely E
J Chemother; 2016 Oct; 28(5):446-9. PubMed ID: 25976829
[No Abstract] [Full Text] [Related]
7. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
Chambers HF; Sande MA
Antimicrob Agents Chemother; 1984 Jul; 26(1):61-4. PubMed ID: 6236747
[TBL] [Abstract][Full Text] [Related]
8. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
Voorn GP; Kuyvenhoven J; Goessens WH; Schmal-Bauer WC; Broeders PH; Thompson J; Michel MF
Antimicrob Agents Chemother; 1994 Mar; 38(3):487-93. PubMed ID: 8203842
[TBL] [Abstract][Full Text] [Related]
9. [Teicoplanin versus cloxacillin, cloxacillin-gentamycin and vancomycin in the treatment of experimental endocarditis caused by methicillin-sensitive Staphylococcus aureus].
Apellaniz G; Valdés M; Pérez R; Martín-Luengo F; García A; Soria F; Gómez J
Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):208-10. PubMed ID: 1830757
[TBL] [Abstract][Full Text] [Related]
10. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
[TBL] [Abstract][Full Text] [Related]
11. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
[TBL] [Abstract][Full Text] [Related]
12. Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance.
Kato Y; Suzuki T; Ida T; Maebashi K; Sakurai M; Shiotani J; Hayashi I
Int J Antimicrob Agents; 2008 Jan; 31(1):64-70. PubMed ID: 18029148
[TBL] [Abstract][Full Text] [Related]
13. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
[TBL] [Abstract][Full Text] [Related]
14. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin and rifampicin singly and in combination in the treatment of experimental Staphylococcus epidermidis endocarditis in the rabbit model.
Tuazon CU; Washburn D
J Antimicrob Chemother; 1987 Aug; 20(2):233-7. PubMed ID: 2959643
[TBL] [Abstract][Full Text] [Related]
16. Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus.
Carper HT; Sullivan GW; Mandell GL
J Antimicrob Chemother; 1987 May; 19(5):659-62. PubMed ID: 2956229
[TBL] [Abstract][Full Text] [Related]
17. Activity of teicoplanin in localized experimental infections in rats.
Arioli V; Berti M; Candiani G
J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
[TBL] [Abstract][Full Text] [Related]
18. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.
Lefort A; Pavie J; Garry L; Chau F; Fantin B
Antimicrob Agents Chemother; 2004 Mar; 48(3):1061-4. PubMed ID: 14982811
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model.
Contrepois A; Joly V; Abel L; Pangon B; Vallois JM; Carbon C
J Antimicrob Chemother; 1988 May; 21(5):621-31. PubMed ID: 2968969
[TBL] [Abstract][Full Text] [Related]
20. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis.
de Górgolas M; Avilés P; Verdejo C; Fernández Guerrero ML
Antimicrob Agents Chemother; 1995 Apr; 39(4):953-7. PubMed ID: 7786002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
